← All diseases Cancer

Chronic lymphocytic leukemia

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchStrongest evidence only (63)Meta-analysis (7)Treatment guideline (3)Phase 3 study (32)Systematic review (13)Randomized trial (8)Clinical trial (588)Review article (208)Early study (phase 1 or 2) (38)Case report (197)Laboratory or animal study (14)Commentary or editorial (62)Retracted publication (2) Studies currently seeking participants only (43)

Filter

Publications and studies (1769)

• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (2026-01-08) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia (2026-01-07) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Safe Accelerated Venetoclax Escalation in CLL (2026-01-07) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation (2026-01-07) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (2026-01-06) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) (2026-01-06) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL (2026-01-06) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) (2026-01-06) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Study of Epcoritamab as a Consolidation Therapy in CLL/SLL (2026-01-06) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (2026-01-05) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (2026-01-05) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphoblastic Leukemia Patients Using Ultrasound Localization Microscopy (2026-01-02) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. LEF1 EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A MARKER FOR DIAGNOSIS AND SURVIVAL PREDICTION (2026-01-02) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Beyond CKD-Associated Pruritus: Paraneoplastic Itch Revealing CLL/SLL in ESRD: A Case Report. (2025/12/30) ♡
• Defective cell-autonomous signalling and antigenic polyreactivity of B-cell receptors from chronic lymphocytic leukaemia stereotyped subset 1. (2025/12/30) ♡
• Exploring the Relation Between Coexisting Chronic Lymphocytic Leukemia and Lung Cancer: Two Case Reports. (2025/12/30) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Successful treatment of rare vaso-vesical fistula with minimally invasive measures despite prior history of radiotherapy: a case report. (2025/12/30) ♡
• Leukemia epidemiology in China: Burden, trends, and determinants in the 21st century. (2025/12/30) ♡
• Nanomechanical and Thermodynamic Alterations of Red Blood Cells in Chronic Lymphocytic Leukemia: Implications for Disease and Treatment Monitoring. (2025/12/29) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia. (2025/12/28) ♡
• Prognostic value of memory B cell subpopulation in patients with chronic lymphocytic leukemia. (2025/12/24) ♡
• Awareness and real-world practices in chronic lymphocytic leukemia: insights from a nationwide survey of Korean hematologists. (2025/12/24) ♡
• Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration route. (2025/12/24) ♡
• Correction: Tosic et al. High Expression Levels of the Long Non-Coding RNAs Lnc-IRF2-3 and Lnc-KIAA1755-4 Are Markers of Poor Prognosis in Chronic Lymphocytic Leukemia. Int. J. Mol. Sci. 2025, 26, 1153. (2025/12/24) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. [A complex diagnostic triad mimicking macrophage activation syndrome: chronic lymphocytic leukemia and tuberculosis (a case report)]. (2025/12/24) ♡
• Darunavir analog precursors target mitochondrial metabolism in multiple myeloma and CLL. (2025/12/23) ♡
• Association of Galectin-9 Soluble Immune Checkpoint with Clinical Prognostic Markers in Patients with Chronic Lymphocytic Leukemia. (2025/12/22) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Solitary Cutaneous Nodule as the Initial Presentation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (2025/12/22) ♡
• Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study. (2025/12/21) ♡
• Role of microRNAs in hematological malignancies research: A bibliometric analysis. (2025/12/19) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Lights and shades of front-line treatment with covalent BTK inhibitors combined with venetoclax in patients with chronic lymphocytic leukemia. (2025/12/18) ♡
• A novel fully human anti-ROR1 antibody PBA-0405 optimized for ADCC, induces potent anti-tumor activity against both solid and hematological malignancies. (2025/12/17) ♡
• Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group. (2025/12/17) ♡
• Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia. (2025/12/15) ♡
• Integrating flow cytometric profile and gene mutation analysis of intact lymph nodes to refine lymphoma immunophenotype. (2025/12/15) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Cryptococcal Infection in a Patient With Chronic Lymphocytic Leukaemia Receiving Acalabrutinib, a Bruton's Tyrosine Kinase Inhibitor: A Case Report. (2025/12/14) ♡
• A new approach for elimination of apoptotic resistance caused by MDM2/MDMX amplification in chronic lymphocytic leukemia: combination of ALRN-6924 and radiofrequency exposure. (2025/12/12) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Ramping up the express stairs: Lisaftoclax in CLL. (2025/12/12) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Ibrutinib-Associated Liver Injury in a Patient with Chronic Lymphocytic Leukemia: Clinical Course and Therapeutic Approach. (2025/12/11) ♡
• Evaluation of the Role of AID-Induced Mutagenesis in Resistance to B-Cell Receptor Pathway Inhibitors in Chronic Lymphocytic Leukemia. (2025/12/10) ♡
• Functional differences between CLL- and ALL-derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL-10 as potential modulatory targets. (2025/12/08) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The role of MRD monitoring and options for CLL management in relapsed/refractory disease. (2025/12/05) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Updates in the management of newly diagnosed chronic lymphocytic leukemia. (2025/12/05) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight. (2025/12/05) ♡
• Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma. (2025/12/05) ♡
• Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China. (2025/12/05) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. (2025/12/04) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. (2025/12/04) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. Reply. (2025/12/04) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. POT1 Tumor Predisposition. (2025/12/04) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.